Ambit Biosciences Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
SAN DIEGO, Nov. 24 /PRNewswire/ -- Ambit Biosciences Corporation announced today that there will be multiple presentations evaluating AC220, a novel second generation FLT3 inhibitor, in AML at the 51st American Society of Hematology Annual Meeting (ASH) to be held in New Orleans, LA ,December 5-8, 2009. An oral presentation will highlight results from an ongoing clinical Phase I monotherapy safety study in adults with acute myeloid leukemia (AML). Additionally, non-clinical data will be presented evaluating the effect of AC220 monotherapy and in combination with chemotherapy.
Data Highlights for AC220 include:
POSTER PRESENTATIONS
Abstract# 2053
AC220 - A FLT3 Inhibitor, Increases Survival in Two Genotypically Distinct FLT3-ITD Models of Acute Myeloid Leukemia and Provides Sustained Protection Following Chronic Administration
Session Name: Acute Myeloid Leukemia - Therapy, excluding Transplantation II
Sunday, December 6, 2009, 6:00 - 8:00pm, Hall E, Poster Board II-45
About Acute Myeloid Leukemia (AML)
Acute myeloid leukemia is a form of blood cancer. According to the American Cancer Society, approximately 13,000 new cases of AML will be diagnosed in the United States in 2008. The median age of a patient with AML is about 67 years old. Standard treatment for patients 60 years or older with AML includes systemic combination chemotherapy. The median survival for patients receiving induction chemotherapy, which is associated with high mortality, is 6-11 months, with shorter survival for patients over the age of 60 years. The five-year survival rate for AML is less than 15 percent due to refractory and relapsed disease associated with standard treatments. According to a report from Decision Resources, the U.S. AML market is expected to more than double by 2015.
CONTACT: M. Scott Salka, Ambit Biosciences, +1-858-334-2101; or Scott
Lerman, The Ruth Group, +1-646-536-7013, slerman@theruthgroup.com
Web site: http://www.ambitbio.com/